



Biotech Daily

Wednesday July 31, 2019

Daily news on ASX-listed biotechnology companies

- * ASX, BIOTECH DOWN: KAZIA UP 13.5%; ALTERITY (PRANA) DOWN 7%
- * AMPLIA RIGHTS RAISE \$689k OF HOPED FOR \$2.2m; TOTAL \$1.2m
- * NEUROSCIENTIFIC: EMTIN-B 'STATISTICALLY SIGNIFICANT' IN RATS
- * CLINUVEL RECEIPTS UP 36% TO \$32m
- * MESOBLAST MILESTONES TAKE RECEIPTS UP 203% TO \$45m
- * AVITA RECEIPTS UP 73% TO \$17m
- * BIONOMICS RECEIPTS UP 22% TO \$9m
- * IQ3 RECEIPTS DOWN 16% TO \$6m
- * IMPEDIMED RECEIPTS DOWN 3% TO \$4.5m
- * PHARMAUST RECEIPTS UP 27% TO \$3.8m
- * G MEDICAL H1 RECEIPTS UP 312% TO \$3.7m
- * RHINOMED RECEIPTS UP 77% TO \$3.1m
- * NUHEARA RECEIPTS DOWN 42% TO \$2.35m
- * MICRO-X RECEIPTS UP 77% TO \$2.3m
- * BIOXYNE RECEIPTS DOWN 5% TO \$1.75m
- * TELIX POSTS \$1.6m H1 MAIDEN RECEIPTS
- * SUDA 1st \$1m RECEIPTS, WITHOUT WESTCOAST
- * INVITROCUE LESS THAN 2 QUARTERS CASH; CAPITAL RAISING
- * REGENEUS HAS LESS THAN TWO QUARTERS CASH; EXPECTS FUNDING
- * GI DYNAMICS: SURGICAL SPECIALISTS OF LOUISIANA JOINS US TRIAL
- * PLATINUM REDUCES TO 7.6% OF ANTISENSE
- * TRIBECA BELOW 5% OF CANN
- * INVESTORS MUTUAL TAKES 9.7% OF MAYNE PHARMA
- * MEMPHASYS APPOINTS SHANE HARTWIG DIRECTOR

MARKET REPORT

The Australian stock market fell 0.47 percent on Wednesday July 31, 2019, with the ASX200 down 32.5 points to 6,812.6 points.

Eleven of the Biotech Daily Top 40 stocks were up, 15 fell, 12 traded unchanged and two were untraded.

Kazia was the best, up five cents or 13.5 percent to 42 cents with 36,372 shares traded.

Amplia and Oncosil climbed more than four percent; Cyclopharm was up 3.7 percent; Avita and Benitec rose more than two percent; Clinuvel and Neuren were up more than one percent; with Medical Developments, Mesoblast, Nanosonics and Resmed up by less than one percent.

Alterity (Prana) led the falls for the second day in a row, down 0.2 cents or 7.1 percent to 2.6 cents with 1.7 million shares traded.

Telix lost 5.7 percent; Dimerix, Genetic Signatures, LBT, Patrys, Proteomics and Resonance fell more than four percent; Opthea and Paradigm were down more than three percent; Cochlear shed 2.1 percent; Antisense and Volpara were down more than one percent; with CSL, Ellex, Polynovo and Starpharma down by less than one percent.

AMPLIA THERAPEUTICS

Amplia says its one-for-two rights issue at 10 cents a share has raised \$688,914 of a hoped-for \$2.2 million; taking the total raised to \$1,218,914.

In June, Amplia said it raised \$360,000 in a placement and would raise \$170,000 in a directors and management placement, pending shareholder approval (BD: Jun 12, 2019). Amplia was up half a cent or 4.2 percent to 12.5 cents.

NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says its Emtin-B shows “statistically significant improvement in both neurite outgrowth and synaptic density” compared to Copaxone for spinal cord injury in rats. Earlier this month, Neuroscientific said Emtin-B improved neurite growth of axons and dendrites and increased nerve cell connections at doses of up to 30 micrograms per millilitre, indicating it would be able to stimulate the reformation of a neuronal network to restore function to injured nerve cells (BD: Jul 3, 2019).

Today, Neuroscientific provided figures showing a comparison of Emtin-B and Copaxone, and in data provided to Biotech Daily, said that the p-value statistical significant difference between Emtin-B and Copaxone on both measures, neurite outgrowth and synaptic density, was $p < 0.01$.

The company said it would consider an Emtin-B study of neuro activity in primary neurons-based models of Parkinson’s disease, Huntington’s disease, motor neuron disease and multiple sclerosis.

Neuroscientific said it was awaiting data for its Emtin-B Alzheimer’s disease mouse model and Emtin-B safety and efficacy study for eye conditions such as glaucoma.

Neuroscientific fell 2.5 cents or 8.3 percent to 27.5 cents with 3.9 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says receipts from customers for the 12 months to June 30, 2019 were up 35.9 percent to \$32,221,000 compared to the previous corresponding period.

Clinuvel says European sales of its Scenesse for erythropoietic protoporphyria for the three months to June 30 were up 25.2 percent to \$13,010,000, with a cash burn of \$8,618,000 for the three months to June 30, cash and cash equivalents of \$54,269,000 at June 30, and an expected outflow of \$5,460,000 for the three months to September 30. Clinuvel climbed 65 cents or 1.75 percent to \$32.51 with 171,989 shares traded.

MESOBLAST

Mesoblast says customer receipts including milestone payments and royalties for the year to June 30, 2019 was up 203.3 percent to \$US30,768,000 (\$A44,692,212).

Mesoblast said receipts included a Tasly Pharmaceutical Group \$US20,000,000 payment, \$US5,409,000 from Takeda Pharmaceutical for a licence agreement and \$US1,000,000 milestone from JCR Pharmaceuticals, with \$US4,359,000 in royalties for its Temcell treatment for graft versus host disease for the year to June 30, of which \$US1,038,000 was for the three months to June 30.

Mesoblast said it had a cash burn of \$US19,085,000 for the three months to June 30, with \$US50,426,000 in cash, and an estimated \$US19,788,000 cash burn to September 30. Mesoblast was up one cent or 0.7 percent to \$1.475.

AVITA MEDICAL

Avita says receipts from customers and government contracts for the year to June 30, 2019 was up 73.1 percent to \$16,586,000.

Avita said receipts from customers for its Recell wound and burn product for the 12 months to June 30 was up 299.3 percent to \$7,232,000, with receipts from its US Biomedical Advanced Research and Development Authority (BARDA) contract up 20.3 percent to \$9,354,000 compared to the previous corresponding period.

The company said that receipts from customers for Recell for the three months to June 30, 2019 was up 774.1 percent to \$3,514,000, with receipts from its BARDA contract down 41.8 percent to \$1,526,000 compared to the previous corresponding period.

Avita said it had a cash burn of \$10,430,000 for the three months to June 30, 2019, with cash and cash equivalents of \$29,155,000 at June 30, and an estimated cash outflow of \$16,900,000 for the three months to September 30, 2019.

Avita was up one cent or 2.35 percent to 43.5 cents with 13.4 million shares traded.

BIONOMICS

Bionomics says receipts from customers for the 12 months to June 30, 2019 were up 21.9 percent to \$8,725,000 compared to previous year.

Bionomics told Biotech Daily the revenue was primarily from the company's two French contract services subsidiaries conducting pre-clinical animal testing and chemistry.

Today, the company said receipts from customers for the three months to June 30 were down 31.9 percent to \$1,920,000 compared to the previous corresponding period.

Bionomics said it had a cash burn of \$6,188,000 for the three months to June 30, with cash and cash equivalents of \$13,986,000 at June 30, and an expected cash burn of \$4,645,000 for the three months to September 30, 2019.

Bionomics fell 0.2 cents or 4.9 percent to 3.9 cents with one million shares traded.

IQ3 CORP

IQ3 says receipts from customers for the year to June 30, 2019 was down 15.5 percent to \$5,589,000 compared to the previous corresponding period.

IQ3 said receipts for advisory and consulting services on life science projects for the three months to June 30 was down 52.6 percent to \$975,000.

The company said it had net cash of \$45,000 for the three months to June 30, 2019, with cash and cash equivalents of \$265,000 at June 30 and an estimated cash outflow of \$915,000 for the three months to September 30, 2019.

IQ3 was untraded at 26 cents.

IMPEDIMED

Impedimed says receipts from customers for the 12 months to June 30, 2019 were down 3.0 percent to \$4,459,000 compared to the previous year.

Impedimed said that customer receipts for three months to June 30 from its bio-impedance spectroscopy technologies including Sozo for heart failure and lymphedema were down 8.4 percent to \$1,196,000 compared to the previous corresponding period.

The company said it had a cash burn for the three months to June 30 of \$5,367,000 with cash and cash equivalents of \$11,330,000 at June 30, and an expected outflow of \$6,400,000 for the three months to September 30, 2019.

Impedimed was unchanged at 14.5 cents with 2.8 million shares traded.

PHARMAUST

Pharmaust says receipts from customers for the year to June 30, 2019 were up 26.6 percent to \$3,800,000 compared to the previous twelve months.

Pharmaust said customer receipts, which came through its subsidiary Epichem from sales of its medicinal chemistry, were up 47.15 percent to \$749,000 for the three months to June 30, compared to the previous corresponding period.

The company said it had a cash burn of \$256,000 for the three months to June 30, with cash and cash equivalents of \$2,098,000 at June 30, and an expected outflow of \$1,650,000 for the three months to September 30, 2019.

Pharmaust was up 0.8 cents or 9.9 percent to 8.9 cents with 4.7 million shares traded.

G MEDICAL INNOVATIONS HOLDINGS

G Medical says receipts from customers for the six months to June 30, 2019 was up 311.7 percent to \$US2,540,000 (\$A3,689,490) compared to the previous period.

G Medical said receipts from its Patch vital signals monitor technology and its Prizma medical smartphone case for the three months to June 30 was up 269.1 percent to \$US1,314,000 (\$A1,908,657).

The company said it had a loan from controlling shareholder and founder Dr Yacov Geva of \$US10,479,000, loan facilities from Israel's Bank Mizrahi Tfahot of \$US2,502,000 and convertible notes of \$US3,492,000.

G Medical said it had cash burn for the three months to June 30, 2019 of \$US2,242,000, with cash and cash equivalents of \$US352,000 at June 30 and an estimated cash outflow of \$US3,250,000 for the three months to September 30.

G Medical was unchanged at 16 cents with 1.4 million shares traded.

RHINOMED

Rhinomed says receipts from customers for the year to June 30, 2019 was up 76.5 percent to \$3,120,000 compared to \$1,768,000 the previous year.

Rhinomed said receipts from customers for the three months to June 30, 2019 was up 244.6 percent to \$1,530,000 for its Mute nasal dilators for sleep apnoea and snoring.

The company said it had a cash burn for the three months to June 30, 2019 of \$1,054,000.

Rhinomed said it had cash and cash equivalents of \$1,456,000 at June 30, 2019 and an estimated cash outflow for the three months to September 30, 2019 of \$1,925,000.

Rhinomed fell two cents or 6.1 percent to 31 cents.

NUHEARA

Nuheara says its receipts from customers for the year to June 30, 2019 were down 42.0 percent to \$2,352,000 compared to the previous year.

Nuheara said customer receipts from its sound filtering and hearing assistance devices for the three months to June 30 were down 75.6 percent to \$325,000.

The company said it had a cash burn of \$1,938,000 for the three months to June 30, with cash and cash equivalents of \$3,220,000, not including \$4,000,000 from its July capital raising (BD: Jul 5, 2019).

Nuheara said it had an expected cash flow of \$4,650,000 for the three months to September 30, 2019, including \$1,400,000 to acquire intellectual property.

Nuheara fell 0.7 cents or 14.6 percent to 4.1 cents with 16.9 million shares traded.

MICRO-X

Micro-X says its receipts from customers for the year to June 30, 2019 were up 77.0 percent to \$2,320,000 compared to the previous year.

Micro-X said customer receipts from its Carestream DRX Revolution Nano digital medical x-ray system for the three months to June 30 were up 131.2 percent to \$941,000.

The company said it had a cash burn of \$2,191,000 for the three months to June 30, with cash and cash equivalents of \$1,603,000 and an expected cash flow of \$4,214,000 for the three months to September 30, 2019.

Micro-X said it had loan facilities for \$3,000,000 with the South Australian Government Financing Authority and with the R&D Capital in relation to a "prepayment loan" on its 2019 Research and Development Tax Incentive.

Micro-X was up one cent or 3.1 percent to 33.5 cents.

BIOXYNE

Bioxyne says receipts from customers for the year to June 30, 2019 fell 4.8 percent to \$1,751,000 compared to the previous twelve months.

Bioxyne said customer receipts from its dietary supplement Lactobacillus fermentum VRI-003 for the three months to June 30 were down 73.6 percent to \$188,000 compared to the previous corresponding period.

The company said it had a cash burn of \$583,000 for the three months to June 30, with cash and cash equivalents of \$1,769,000 at June 30 and an expected cash burn of \$540,000 for the three months to September 30, 2019.

Bioxyne was unchanged at two cents.

TELIX PHARMACEUTICALS

Telix says it has posted maiden receipts for the six months to June 30, 2019 of \$1,644,000, of which \$942,000 was in the three months to June 30.

Telix said the customer receipts were for sales of its TLX591-CDx or Illumet, which was commercially available as a cold kit for the imaging of metastatic prostate cancer.

The company said the kit was available on a limited basis as an investigational product for an authorized clinical trial in the US, on a named patient basis in Europe and the UK, through the special access scheme in Australia and for compassionate use in the rest of the world, but had not received marketing authorization in any jurisdiction.

Telix said it had cash burn for the three months to June 30, 2019 of \$2,029,000, with cash and cash equivalents of \$19,436,000 at June 30, and an estimated cash outflow for the three months to September 30 of \$7,477,000.

Telix fell 8.5 cents or 5.7 percent to \$1.41.

SUDA PHARMACEUTICALS

Suda says customer receipts for the year to June 30, 2019 were down 79.2 percent to \$1,051,000, but were its first without subsidiary West Coast Surgical & Medical Supplies.

In 2018, Suda said it completed the \$1,728,757 sale of Westcoast (BD: Mar 8, 2018).

Today, Suda chief executive officer Stephen Carter told Biotech Daily that its customer receipts came from licencing of the Oromist oro-mucosal spray technology.

The company said customer receipts for the three months to June 30, 2019 were \$118,000, with a \$797,000 cash burn for the period.

Suda said it had cash and cash equivalents at June 30 of \$4,314,000 and an expected outflow of \$933,000 for the three months to September 30, 2019.

Suda fell 0.05 cents or 11.1 percent to 0.4 cents with 9.4 million shares traded.

INVITROCUE

Invitrocue says its net operating cash burn for the three months to June 30, 2019 was \$1,007,000 with cash at the end of the quarter of \$361,000.

Invitrocue said customer receipts for the three months to June 30 were \$198,000 with an expected outflow of \$1,000,000 for the three months to September 30, 2019.

The company told Biotech Daily it was expecting a revenue increase, with quarter-on-quarter improvements expected to continue, as well as a potential capital raising.

Invitrocue was untraded at 6.5 cents.

REGENEUS

Regeneus says its net operating cash burn for the three months to June 30, 2019 was \$1,501,000 with cash at the end of the quarter of \$255,000.

Regeneus said it had loan facilities of \$600,000 at June 30, with an expected outflow of \$2,130,000 for the three months to September 30, 2019.

The company said it expected additional funding by September 30 which would "present the opportunity to restructure the company in line with its 'Revised Strategy Focus' announced [on] July 22, 2019" (BD: Jul 22, 2019).

In the July 22, 2019 announcement, Regeneus said it was "finalizing a range of initiatives to ensure costs and operations are aligned to execute its revised strategy in an efficient and effective manner".

Regeneus was untraded at 8.5 cents.

GI DYNAMICS

GI Dynamics says the Metairie-based Surgical Specialists of Louisiana have joined its US pivotal trial of Endobarrier duodenum insert for obesity and type 2 diabetes.

GI Dynamics said single therapy euglycemic procedure (Step-1) trial would begin enrolling patients “during the second half of 2019”.

The company previously said the University of Michigan, Texas Baylor College of Medicine, Brigham and Women’s Hospital and Thomas Jefferson University hospital had been contracted as trial sites (BD: Jun 13, Jul 11, Jul 23, 2019).

GI Dynamics was up 0.1 cents or 3.1 percent to 3.4 cents.

ANTISENSE THERAPEUTICS

Platinum Investment Management says it has reduced its substantial shareholding in Antisense from 35,984,848 shares (8.57%) to 31,755,652 shares (7.56%).

The Sydney-based Platinum said that between July 26 and July 30, 2019, it disposed of 4,229,196 shares for \$212,690.94 or five cents a share.

Antisense fell 0.1 cents or 1.9 percent to 5.1 cents with 2.8 million shares traded.

CANN GROUP

Sydney’s Tribeca Investment Partners says it has ceased its substantial shareholding in Cann Group.

Last week, Tribeca said it held 7,167,485 shares (5.05%) of Cann (BD: Jul 23, 2019).

Today, Tribeca said that on July 26 and 30, 2019 it sold 117,314 shares for \$258,929 or \$2.207 a share and Biotech Daily calculated that Tribeca continued to hold 7,050,171 shares or 4.97 percent of the company.

Cann Group was unchanged at \$2.18.

MAYNE PHARMA GROUP

Investors Mutual says it has increased its holding in Mayne Pharma from 134,101,493 shares (8.47%) to 154,226,093 shares (9.74%).

The Sydney-based Investors Mutual said that between May 22 and July 30, 2019 it bought 20,124,600 shares, with the single largest purchase 1,300,000 shares for \$673,010 or 51.7 cents a share.

Mayne was up half a cent or 0.95 percent to 53 cents with 4.2 million shares traded.

MEMPHASYS

Memphasys says it has appointed Shane Hartwig as a non-executive director, effective immediately.

Memphasys said Mr Hartwig had more than 30 years’ experience in the finance industry and was the founder and director of the Sydney-based Peloton Advisory.

The company said Mr Hartwig was a company secretary and accountant and held a Bachelor of Business from the Perth’s Curtin University of Technology.

Memphasys was up 0.2 cents or 3.9 percent to 5.3 cents.